CD38 and Duchenne muscular dystrophy: To test whether CD38 inhibition could also be beneficial in human myotubes, we used SAR650984 (isatuximab), an anti‐CD38 monoclonal antibody, on human DMD myotubes, also known to display pathological spontaneous Ca2+ activity (Vianello et al, 2014).